Neuronetics Posts $1.69M Third-Quarter Loss
Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment
Neutral
Importance
7
Price
$2.32
Mkt Cap
$172.206M
52W Low
$0.8
52W High
$3.44
52W Position
190% above low
Off High
33% below high
Rel. Volume
1.1× avg
Market data snapshot near publication time
STIM has more than doubled off its 52-week low of $0.8.
Summary
Neuronetics reported a third-quarter loss of $1.69 million on revenue of $42 million, up from the $41.6 million posted in Q2. The bigger overhang remains the going-concern warning disclosed with Q2 results, tied to a projected debt covenant breach in March 2027 — a small quarterly loss does little to change that math.
At the time of this announcement, STIM was trading at $2.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172.2M. The 52-week trading range was $0.80 to $3.44. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.
Price Chart
STIM - Latest Insights
STIM
Nov 16, 2026, 7:30 AM EST
Price at Filing:
$1.47
Real-time Price:
$1.25
Change:
-$0.2166 (-15%)
Market Cap:
$97.16M
STIM
Nov 10, 2026, 10:40 PM EST
Price at Filing:
$1.76
Real-time Price:
$1.25
Change:
-$0.5103 (-29%)
Market Cap:
$97.16M
STIM
Nov 10, 2026, 5:01 PM EST
Price at Filing:
$1.81
Real-time Price:
$1.25
Change:
-$0.560 (-31%)
Market Cap:
$97.16M
STIM
Nov 10, 2026, 4:10 PM EST
Price at Filing:
$1.80
Real-time Price:
$1.25
Change:
-$0.5501 (-31%)
Market Cap:
$97.16M
STIM
Nov 10, 2026, 4:01 PM EST
Price at Filing:
$1.80
Real-time Price:
$1.25
Change:
-$0.5501 (-31%)
Market Cap:
$97.16M